Evidence / Pekar et al. · 2024
A one-year spermidine follow-up without a control group
Selected research. Study type, product relevance and limitations are shown separately.
Editorial study summary
- Study type
- Single-arm human follow-up. The abstract describes no placebo or control group.
- Product relevance
- Relevant ingredient evidence from a dietary follow-up, with weak evidence because there was no control group.
- Sample or population
- 45 nursing-home residents in Hart bei Graz, Austria.
- Studied dose
- 3.3 mg of spermidine per day in the diet.
- Duration
- 1 year.
- Finding
- The mean MMSE score was 5 points higher at follow-up than at baseline (p < 0.001). This was a within-group comparison.
- Limitations
- Weak evidence. Without a control group, practice effects and changes in care cannot be ruled out. The change cannot be attributed to spermidine on this design alone.
- Study quality
- The PubMed abstract was reviewed. The uncontrolled design limits causal interpretation.
- Funding and disclosures
- The authors declared no competing interests. Funding was not verified from the approved source material.
The studies discussed here examine ingredients or other formulations. They do not establish results for this DR.MORGAN finished product.